Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to
estimate the improvement in PFS (compared to control subjects) and evaluate the safety and
tolerability of AMG 386 in combination with paclitaxel in the treatment of subjects with
advanced recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Primary Outcome Measure:
• Progression free survival (PFS)
Secondary Outcome Measures:
- Object Response Rate (ORR), duration of response (DOR). CA-125 response rate
- Safety and Tolerability
- Change and duration of change on blood levels of CA-125